Lorlatinib to Deliver High Response Rate in the Lung Cancer Patients

Release Date: 23-Nov-2020

Reduced cancer size was observed in the patients suffering from anaplastic lymphoma when treated with (ALK)-inhibitor lorlatinib as well as reduced mortality rate in the patients was observed in the patients suffering from ALK-positive non-small-cell lung cancer (NSCLC). Brain metastasis in the patients suffering from ALK-positive patients is estimated to develop fast. Although some ALK inhibitors are in development phase since 2008 but there are various impacts that are still found in the patients who undergo the treatment such as high rate of relapse and metastatic spread. Another drug which is considered to be under third -generation of ALK inhibitor is also there called as Lorlatinib.

A group of researchers from Massachusetts General Hospital have conducted a clinical research study which combined the study of impact of lorlatinib with crizotinib. A total of 296 patients were enrolled in the study. The primary aim of the researchers conducting the clinical trial was to gather information about the progression-free survival of the combination whereas some of the secondary aims of the researchers were to evaluate about objective response and intracranial response of the combination.

The enrolled patients who were given lorlatinib, the progression free survival rate was observed to be 78% and 76% objective response rate and the other group who only received crizotinib only received 39% progression free survival and 58% objective response rate. Some of the adverse effects that were observed in the patients were hyperlipidemia, edema, increased weight and peripheral neuropathy. It was concluded by the researchers patients who received lorlatinib had significantly longer progression-free survival and a higher frequency of intracranial response when compared with the other group who only received crizotinib.